Disc Medicine (NASDAQ:IRON – Get Free Report) had its price target raised by equities research analysts at Morgan Stanley from $92.00 to $104.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley‘s price target indicates a potential upside of 36.64% from the stock’s previous close.
Several other research analysts have also issued reports on IRON. HC Wainwright raised their target price on shares of Disc Medicine from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Wells Fargo & Company lifted their price target on shares of Disc Medicine from $86.00 to $124.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 20th. Truist Financial boosted their price target on shares of Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Thursday, October 15th. Finally, Wedbush increased their price objective on shares of Disc Medicine from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, October 19th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $125.27.
Check Out Our Latest Report on IRON
Disc Medicine Price Performance
Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.10. As a group, research analysts anticipate that Disc Medicine will post -6.20 earnings per share for the current year.
Insider Buying and Selling
In other Disc Medicine news, insider William Savage sold 16,035 shares of Disc Medicine stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $85.09, for a total value of $1,364,418.15. Following the transaction, the insider owned 63,445 shares of the company’s stock, valued at approximately $5,398,535.05. The trade was a 20.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Jonathan Yu sold 8,796 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at $4,515,410.88. This trade represents a 13.94% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 150,277 shares of company stock valued at $11,877,059. 3.76% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Disc Medicine
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Disc Medicine in the second quarter valued at about $180,502,000. Assenagon Asset Management S.A. boosted its position in shares of Disc Medicine by 191.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after buying an additional 735,300 shares during the period. Opaleye Management Inc. grew its holdings in shares of Disc Medicine by 103.1% during the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after buying an additional 434,000 shares in the last quarter. Palo Alto Investors LP bought a new position in shares of Disc Medicine during the second quarter worth about $30,473,488. Finally, Octagon Capital Advisors LP bought a new position in shares of Disc Medicine during the first quarter worth about $17,264,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.
About Disc Medicine
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.
Recommended Stories
- Five stocks we like better than Disc Medicine
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
